NIH RePORTER
Cure8 regulatory brief
Why This Matters
This project explores a specific molecular pathway (WNT2B → NF-κB/IL‑6) that may protect the colon from inflammation. If validated, it could identify a new therapeutic target for IBD and help explain why some people develop worse colitis.
Who Should Pay Attention
Researchers studying Wnt signaling, immune pathways, and IBD; translational scientists interested in new therapeutic targets; clinicians following IBD research advances.
Study Snapshot
Story typeRegulatory
Evidence typeFunded research project
Study statusFunded
Source depthResearch project record
What To Know
This is a funded research project (project-record) proposing preclinical and translational studies to define WNT2B’s role in colitis.
The team plans mechanistic experiments in mice and human-relevant models to test how WNT2B from mesenchymal fibroblasts affects NF-κB, IL-6, and innate immune cell recruitment, and to test whether increasing WNT2B expression can prevent or lessen colitis.
Planned work appears to include animal DSS colitis models, knockout and overexpression approaches, and studies in human-derived tissues or organoids. This proposal is about target discovery and early-stage therapeutic potential rather than a completed clinical trial or an approved treatment.
Keep In Mind
This entry is a funded NIH project record describing planned and ongoing preclinical/translational research. It does not report clinical trial results or an approved therapy; findings will require peer review and clinical validation before changing care.
Source Details
Review the original publication for the complete reporting, methods, and context.
Funded research project
Evidence type derived from source or registry metadata.
PublicationNIH RePORTER
AuthorsAmy E OConnell
InstitutionNEMOURS CHILDREN'S HOSPITAL, DELAWARE
Study typeFunded Research Project
Indexed viaNIH RePORTER
Source typeFunded research record
PublishedSep 1, 2026, 12:00 AM
Content availableResearch project record
Funding disclosed by the source: National Institute of Diabetes and Digestive and Kidney Diseases - R01DK142812 - $719,124
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
INTERROGATING GCPII-MEDIATED GLUTAMATE SIGNALING IN THE GASTROINTESTINAL TRACT AND ITS ROLE IN INTESTINAL HOMEOSTASIS
This project studies a novel enzyme target (GCPII) that is reportedly upregulated in IBD and may change glutamate signaling and barrier function; understanding it could point to new treatment strategies for people whose...
Modulating Microbial Choline Degradation to Prevent and Treat Intestinal Fibrosis in Inflammatory Bowel Diseases
Intestinal fibrosis and strictures remain a major cause of surgery and obstruction in Crohn’s disease, and current anti-inflammatory drugs don’t reliably prevent fibrosis. If microbial choline degradation promotes...
Defining the origins and effector function of avb6-specific autoantibodies in ulcerative colitis
Researchers found that nearly all people with UC have high-titer autoantibodies to the epithelial integrin αvβ6 that can precede disease and associate with worse outcomes. Understanding whether and how these antibodies...